New Cholesterol Guidelines for Longevity (2010)

2011 ◽  
pp. 124-136 ◽  
Author(s):  
Harumi Okuyama ◽  
Tomohito Hamazaki ◽  
Yoichi Ogushi
Keyword(s):  
Cholesterol Guidelines

Cholesterol Guidelines Debate

PEDIATRICS ◽  
2001 ◽  
Vol 107 (5) ◽  
pp. 1229-1230 ◽  
Author(s):  
S. S. Gidding; ◽  
T. B. Newman ◽  
A. M. Garber
Keyword(s):  
Cholesterol Guidelines

scholarly journals PCSK9 INHIBITOR INITIATION AMONG VETERANS ACCORDING TO THE 2018 AHA/ACC BLOOD CHOLESTEROL GUIDELINES

2020 ◽  
Vol 75 (11) ◽  
pp. 233
Author(s):  
Catherine G. Derington ◽  
Jordan King ◽  
Robert S. Rosenson ◽  
Bharat Poudel ◽  
Keri Monda ◽  
...  
Keyword(s):  
Blood Cholesterol ◽  
Pcsk9 Inhibitor ◽  
Cholesterol Guidelines

Statin Use With the ATP III Guidelines Compared to the 2013 ACC/AHA Guidelines in HIV Primary Care Patients

2016 ◽  
Vol 30 (1) ◽  
pp. 64-69 ◽  
Author(s):  
Pansy Elsamadisi ◽  
Agnes Cha ◽  
Elise Kim ◽  
Safia Latif
Keyword(s):  
Statin Therapy ◽  
Retrospective Chart Review ◽  
Population Based ◽  
Risk Scores ◽  
Atherosclerotic Cardiovascular Disease ◽  
Laboratory Test Results ◽  
Hiv Primary Care ◽  
Cholesterol Guidelines ◽  
Level Of Agreement ◽  
Statin Use

Background: The 2013 Cholesterol Guidelines include a new atherosclerotic cardiovascular disease (ASCVD) risk calculator that determines the 10-year risk of coronary heart disease and/or stroke. The applicability of this calculator and its predecessor, the Framingham risk score (FRS) in Adult Treatment Panel (ATP) III, has been limited in patients with HIV. The objective of this study was to compare the risk scores of ASCVD and FRS in the initiation of statin therapy in patients with HIV. Methods: We conducted a retrospective chart review of patients with HIV on statin therapy from October 1, 2013, to April 1, 2014. Data collection included patient demographics, pertinent laboratory test results, and medication list. The primary end point evaluated the level of agreement between the guidelines. Results: Of 155 patients who met the inclusion criteria, 116 were treated similarly with both guidelines. This showed a moderate level of agreement ( P < .001). Forty-eight of 86 patients requiring statins were placed on the correct intensity statin using the 2013 guidelines. Regardless of which guideline, a majority of patients required statin therapy. Conclusion: A moderate agreement was found between both guidelines in terms of statin use when applied to an HIV patient population. Based on the 2013 guidelines and taking into account drug interactions with antiretrovirals, 44.2% of the patients were treated with an incorrect statin intensity.

scholarly journals Lower is better: ezetimibe and PCSK9 inhibition join the mainstream of lipid‑lowering therapy

2016 ◽  
Vol 7 (1) ◽  
pp. 17-25
Author(s):  
Cezary Wójcik
Keyword(s):  
Statin Therapy ◽  
Heart Association ◽  
Lipid Lowering ◽  
Atherosclerotic Cardiovascular Disease ◽  
Lipid Lowering Therapy ◽  
Pcsk9 Inhibitors ◽  
Level Of Evidence ◽  
Cholesterol Guidelines ◽  
Pcsk9 Inhibition ◽  
Current Guidelines

The focus of 2013 cholesterol guidelines to prevent atherosclerotic cardiovascular disease (ASCVD) released by American College of Cardiology (ACC) and American Heart Association (AHA) is the administration of high intensity statin therapy to specific four groups of patients, which were found to benefit the most from such therapy. They no longer promote achieving specific LDL-C goals with a combination therapy involving statins and other drugs, as advocated by the former ATP-III guidelines as well as current guidelines of European Atherosclerosis Society, International Atherosclerosis Society or National Lipid Association. Such approach has been dictated by the strict reliance on randomized controlled trials as the only acceptable level of evidence. However, since publication of the 2013 ACC/AHA guidelines, cardiovascular benefits of ezetimibe added to statin therapy have been established. Moreover, the advent of PCSK9 inhibitors, providing a powerful supplement and/or alternative to statin therapy, further complicates the therapeutic horizon in dyslipdiemias. It is very likely that a new set of ACC/AHA guidelines will be published in 2016, with a return of specific LDL-C and Non-HDL-C goals of therapy as well as integration of drugs other than statins. As the treatment of dyslipidemias becomes more complex, the need for the subspecialty of clinical lipidology to be officially recognized becomes more evident.

scholarly journals New Cholesterol Guidelines for Children?

Circulation ◽  
2006 ◽  
Vol 114 (10) ◽  
pp. 989-991 ◽  
Author(s):  
Samuel S. Gidding
Keyword(s):  
Cholesterol Guidelines

scholarly journals Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018 AHA/ACC Cholesterol Guidelines

2019 ◽  
Vol 74 (5) ◽  
pp. 712-714 ◽  
Author(s):  
Salim S. Virani ◽  
Julia M. Akeroyd ◽  
Sidney C. Smith ◽  
Mouaz Al-Mallah ◽  
Thomas M. Maddox ◽  
...  
Keyword(s):  
High Risk ◽  
Cholesterol Guidelines ◽  
Very High
Sign in / Sign up

Export Citation Format

Share Document